Skip to content

Effects of Health Care Provider-mediated, Remote Coaching System Through the PDA-type Glucometer and the Internet on Diabetes Management

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01041144
Enrollment
115
Registered
2009-12-31
Start date
Unknown
Completion date
Unknown
Last updated
2009-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glucose Control, Internet Communication, Lifestyle Intervention, Type 2 Diabetes

Keywords

Diabetes, PDA, Internet, HbA1c

Brief summary

The purpose of this study is to investigate the effectiveness of the new diabetes care delivery system applied to preexisting public health care resources through advanced information technologies such as PDA-type glucometer and the Internet on the glycemic control of type 2 diabetes patients lived in isolated rural area. The investigators conducted a prospective, randomized, controlled trial in patients with type 2 diabetes for 12 weeks. The intervention group was treated with the new health care delivery system, where diabetes center provided specialized management, mediated by nurse of primary health care posts using the Internet and the PDA-type glucometer, while the control group with conventional health care. HbA1c, fasting plasma glucose and lipids levels were measured at baseline and follow-up.

Interventions

BEHAVIORALlifestyle counseling

supporting diabetes patients using Internet communication

Sponsors

Ministry for Health Welfare and Family Affairs
CollaboratorUNKNOWN
The Catholic University of Korea
Lead SponsorOTHER

Study design

Primary purpose
SUPPORTIVE_CARE

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years

Inclusion criteria

* Type 2 diabetes patients * Aged ≥ 40 years * Baseline HbA1c of 7.0 to 11.0 % who had been already followed up for more than 6 months in the health care post

Exclusion criteria

* Participants with diagnosed or suspected disease of the liver, pancreas, endocrine organs, or kidney * Ischemic heart disease or cerebrovascular disease or a history of such disease * A creatinine level \> 0.133 mmol/L * Treatment with an intensified insulin regimens and those unable .

Design outcomes

Primary

MeasureTime frame
HbA1c

Secondary

MeasureTime frame
PP2hr Lipid profile

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026